Home
Genosity

Genosity Market Share Analysis for April 2026

Industry: N/A

Domaingenosity.com

Year Founded2016

Employees51 - 200

Annual Revenue$5M - $10M

Genosity

Genosity (including company regionals)

genosity.com

See more website traffic and engagement information

Genosity Revenue up to April 2026 is 5M - 10M

revenue generated by Genosity top domains

Genosity top domains revenue over 3 years

Revenue for Genosity top domains

genosity.com5M - 10M

See more with Sales Intelligence

Total visits to Genosity's top domains

Understand Genosity market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Genosity's top domains

Analyze Genosity engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Genosity's top domains

See how Genosity keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Genosity top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Genosity

These are the website technologies, by industry, used by Genosity top domains

Widget (4)

Twemoji

Email Services (2)

G Suite

Mobile (2)

Meta Viewport

Advertising (1)

PubMatic

More Technologies

3

See all

News & Signals from Genosity

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsGenosity acquires Ciitizen.In October 2020, it bought ArcherDX Inc., in February 2021 bought microbiome sequencing company One Codex, two months later acquired genomic laboratory services company Genosity Inc. and last September bought Ciitizen Corp., a health technology company.

NewsGenosity partners with Invitae Corp.Genosity has already worked with Invitae on a number of projects and clinical research trials in the past.

NewsInvitae Corp acquired Genosity for $200M on Apr 5th '21.Under the terms of the agreement, Invitae will acquire Genosity for approximately $200 million, consisting of (i) approximately $120 million in cash and (ii) approximately $80 million in shares of Invitae common stock (based upon a trailing average closing price prior to the date of closing but subject to certain potential adjustments), with such stock and cash consideration subject to reduction based upon certain debt and transaction expenses of Genosity determined at closing.